Role of Vitamin B Complex as an Add-on Therapy to Diclofenac in Patients with Primary Osteoarthritis of the Knee

IF 0.4 Q4 PHARMACOLOGY & PHARMACY Journal of Pharmacology & Pharmacotherapeutics Pub Date : 2021-04-01 DOI:10.4103/jpp.jpp_32_21
J. Kaur, S. Rani, A. Gulia, G. Bhutani, Sanjeev Kumar, Arvind Narwat
{"title":"Role of Vitamin B Complex as an Add-on Therapy to Diclofenac in Patients with Primary Osteoarthritis of the Knee","authors":"J. Kaur, S. Rani, A. Gulia, G. Bhutani, Sanjeev Kumar, Arvind Narwat","doi":"10.4103/jpp.jpp_32_21","DOIUrl":null,"url":null,"abstract":"Objective: This study was conducted with the aim to evaluate the efficacy and safety of Vitamin B complex as an add-on therapy to diclofenac in patients with primary osteoarthritis (OA) of the knee. Materials and Methods: In this prospective, open-labeled, randomized, and comparative clinical study, a total of 130 patients of age >40 years with primary OA of knee attending orthopedics OPD were randomly allocated into two groups of 65 each, i.e., Group D and Group B. In Group D, patients received tablet diclofenac 75 mg and in Group B, patients received tablet Vitamin B complex along with diclofenac once daily for 4 weeks, respectively. Clinical assessment was done at baseline and at the end of 4 weeks and 8 weeks by the visual analog scale (VAS), WOMAC index, and Lequesne index. Results: During the intergroup comparison, it was found that Vitamin B complex as an add-on therapy to diclofenac produced statistically significant reduction in mean VAS pain score (P < 0.05). However, the difference in mean WOMAC index and Lequesne index was not statistically different at 4 and 8 weeks between the two groups (P > 0.05). Mild side effects were seen at 4 weeks, but no side effects persisted up to 8 weeks in both the groups. Conclusion: The present study suggested that Vitamin B complex as an add-on therapy was found to cause a significant reduction in pain score. It could be a promising drug in patients with OA to improve the analgesic effect, when combined can reduce the dose of diclofenac, thereby minimizing the side effects.","PeriodicalId":16761,"journal":{"name":"Journal of Pharmacology & Pharmacotherapeutics","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacology & Pharmacotherapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jpp.jpp_32_21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: This study was conducted with the aim to evaluate the efficacy and safety of Vitamin B complex as an add-on therapy to diclofenac in patients with primary osteoarthritis (OA) of the knee. Materials and Methods: In this prospective, open-labeled, randomized, and comparative clinical study, a total of 130 patients of age >40 years with primary OA of knee attending orthopedics OPD were randomly allocated into two groups of 65 each, i.e., Group D and Group B. In Group D, patients received tablet diclofenac 75 mg and in Group B, patients received tablet Vitamin B complex along with diclofenac once daily for 4 weeks, respectively. Clinical assessment was done at baseline and at the end of 4 weeks and 8 weeks by the visual analog scale (VAS), WOMAC index, and Lequesne index. Results: During the intergroup comparison, it was found that Vitamin B complex as an add-on therapy to diclofenac produced statistically significant reduction in mean VAS pain score (P < 0.05). However, the difference in mean WOMAC index and Lequesne index was not statistically different at 4 and 8 weeks between the two groups (P > 0.05). Mild side effects were seen at 4 weeks, but no side effects persisted up to 8 weeks in both the groups. Conclusion: The present study suggested that Vitamin B complex as an add-on therapy was found to cause a significant reduction in pain score. It could be a promising drug in patients with OA to improve the analgesic effect, when combined can reduce the dose of diclofenac, thereby minimizing the side effects.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
维生素B复合物作为双氯芬酸辅助治疗原发性膝骨性关节炎的作用
目的:本研究旨在评估维生素B复合物作为双氯芬酸辅助治疗原发性膝关节骨性关节炎(OA)的疗效和安全性。材料和方法:在这项前瞻性、开放标记、随机和比较的临床研究中,共有130名年龄>40岁的膝关节原发性OA患者被随机分为两组,每组65人,即D组和B组,患者分别接受片剂维生素B复合物和双氯芬酸,每天一次,持续4周。在基线以及4周和8周结束时,通过视觉模拟评分(VAS)、WOMAC指数和Lequesne指数进行临床评估。结果:在组间比较中,发现维生素B复合物作为双氯芬酸的附加治疗使平均VAS疼痛评分显著降低(P<0.05)。但两组在4周和8周时的平均WOMAC指数和Lequesne指数差异无统计学意义(P>0.05)。4周时出现轻度副作用,但两组患者均未出现持续8周的副作用。结论:本研究表明,维生素B复合物作为一种附加疗法可以显著降低疼痛评分。它可能是一种很有前途的改善OA患者镇痛效果的药物,当联合使用时可以减少双氯芬酸的剂量,从而最大限度地减少副作用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.40
自引率
0.00%
发文量
37
期刊最新文献
Allelic Variants in the Warfarin-related Genes VKORC1 and CYP2C9 in a Western Saudi Population N-Acetyl-l-Cysteine Ameliorations RenalFunction Early After Renal Ischemia and Reperfusion; it is not Protective over a LongTerm under a High-Sodium Diet in Rats Rationalization of Antibiotic Prescription: Modulation of the Gut Microbiome and Possibilities of Minimizing the Risks for the Development of Antibiotic Resistance—A Narrative Review The Science of Antioxidants: Balancing thePros and Cons for Our Health Use of Fixed-dose Combination Therapy with Remogliflozin and Vildagliptin as an Add-on Drug in Improving the Glycemic Control of Type 2 Diabetes Mellitus: An Observational Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1